FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Thierry Lecomte et al.|New England Journal of Medicine|2018Cited by 2.8k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, Jean-François Bosset et al.|The Lancet Oncology|2021Cited by 1.3k
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThierry Conroy, Antoine Adenis, Marie‐Pierre Galais et al.|The Lancet Oncology|2014Cited by 446
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal CancerJean‐Pierre Gérard, Thierry Conroy, D. Azria et al.|Journal of Clinical Oncology|2012Cited by 431
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.Thierry Conroy, Christophe Borg, Najib Lamfichekh et al.|Journal of Clinical Oncology|2020Cited by 177